Werewolf Therapeutics Inc (HOWL) Stock Price, Quote & News

Company Profile

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activa...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 952 0555

Website: werewolftx.com

Address:

200 Talcott Ave, 2nd Floor, Watertown, United States

VincM Feb. 6 at 8:30 PM

$HOWL 👀$1 🎯

0 · Reply

swingtraderqueen Feb. 6 at 4:11 PM

$HOWL so underrated and undervalued. Price pt $5

0 · Reply

Spartrap Feb. 5 at 1:57 PM

$HOWL how is the market going to react to the deficiency notice that's probably being announced today AH? Good results for JZP898 could probably save this company, with maybe JAZZ buying them out, but the study history update from Feb 25 (showing they switched ORR in monotherapy from primary to secondary endpoint) basically already admits they are seeing jack shit in mono..

1 · Reply

FrankyNyc Feb. 2 at 3:39 PM

$HOWL someone is buying up shares? how else did the stock bounce back green? If we close above 0.70 no doubt someone is accumulating

0 · Reply

FrankyNyc Feb. 2 at 3:09 PM

$HOWL over 200k in the first 30 minutes of trading. Definitely feels like Luke and his associates are still unloading

0 · Reply

FrankyNyc Feb. 2 at 2:52 PM

$HOWL Does anyone know if Luke Evnin is still unloading shares? so far theres no update of him unloading. I was hoping if he eventually stops the stock will bounce back to 1.00

0 · Reply

FrankyNyc Jan. 30 at 11:16 PM

$HOWL Today was an awful day most stocks took a hit. As for howl it closed down to 0.66 If not mistaken 422,000 in volume. If my numbers are way off dont mind if you folks give me the correct number. Whats odd is after hours Ive noticed volume was increasing after 4pm. its 6.12 pm and volume has reached 689,501 ??? thats a difference of 267,501 Anyone want to chime in. Much appreciated.

1 · Reply

FrankyNyc Jan. 30 at 5:30 PM

$HOWL anemic volume today especially compared to january 28, when it had 1,045,800 and popped to 0.80 Last update was on December 18. We need an update.

0 · Reply

FrankyNyc Jan. 29 at 4:17 PM

$HOWL Hopefullly we stay above 0.70 and close green.

1 · Reply

FrankyNyc Jan. 29 at 2:57 PM

$HOWL Hmmm did Luke Evnin and his cronies kill the momentum?

0 · Reply

Werewolf Therapeutics Announces Pipeline and Business Updates

Nov 7, 2025, 9:00 AM EST - 3 months ago

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Nov 4, 2025, 7:00 AM EST - 3 months ago

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 8, 2025, 8:00 AM EDT - 4 months ago

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

Oct 3, 2025, 9:00 AM EDT - 4 months ago

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Sep 2, 2025, 8:00 AM EDT - 5 months ago

Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 7:00 AM EDT - 6 months ago

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 9, 2025, 8:00 AM EDT - 7 months ago

Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit

Jun 12, 2025, 8:00 AM EDT - 8 months ago

Werewolf Therapeutics to Participate in the BIO International Convention

May 29, 2025, 8:00 AM EDT - 9 months ago

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

May 20, 2025, 4:01 PM EDT - 9 months ago

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

May 13, 2025, 8:00 AM EDT - 9 months ago

Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit

May 8, 2025, 7:00 AM EDT - 9 months ago

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 8:05 AM EDT - 9 months ago

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

May 5, 2025, 8:00 AM EDT - 9 months ago

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

Apr 17, 2025, 8:00 AM EDT - 10 months ago

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

Mar 31, 2025, 8:00 AM EDT - 11 months ago

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 11, 2025, 7:00 AM EDT - 11 months ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 4, 2025, 8:00 AM EST - 1 year ago

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

Feb 24, 2025, 7:30 AM EST - 1 year ago

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

Jan 13, 2025, 8:00 AM EST - 1 year ago

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

Nov 20, 2024, 8:00 AM EST - 1 year ago

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 7, 2024, 9:02 AM EST - 1 year ago

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Aug 8, 2024, 7:05 AM EDT - 1 year ago

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 1, 2024, 10:04 AM EDT - 1 year ago

Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Jun 1, 2024, 9:00 AM EDT - 1 year ago

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

May 30, 2024, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

May 23, 2024, 5:00 PM EDT - 1 year ago

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

May 3, 2024, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 24, 2024, 10:05 AM EDT - 1 year ago

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Apr 5, 2024, 4:30 PM EDT - 2 years ago

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

Apr 4, 2024, 4:57 PM EDT - 2 years ago

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

Apr 4, 2024, 4:30 PM EDT - 2 years ago

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

Mar 7, 2024, 7:00 AM EST - 2 years ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 6, 2024, 8:00 AM EST - 2 years ago

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

Mar 5, 2024, 4:30 PM EST - 2 years ago

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

Jan 8, 2024, 7:00 AM EST - 2 years ago

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

Jan 4, 2024, 4:05 PM EST - 2 years ago

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

Dec 28, 2023, 7:09 PM EST - 2 years ago

Werewolf Therapeutics: Still In The Race To Develop Next Generation Cytokines

Nov 22, 2023, 7:00 AM EST - 2 years ago

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

Nov 14, 2023, 4:25 PM EST - 2 years ago

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 5:14 PM EST - 2 years ago

Werewolf Therapeutics: Possibly A Transformative IL-2, But Still Early Days

Nov 3, 2023, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Oct 31, 2023, 9:00 AM EDT - 2 years ago

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 27, 2023, 9:00 AM EDT - 2 years ago

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 11, 2023, 4:05 PM EDT - 2 years ago

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

Aug 25, 2023, 4:48 PM EDT - 2 years ago

Werewolf: Q4 2023 Data Readout And Enhancement Of Validated Targets

VincM Feb. 6 at 8:30 PM

$HOWL 👀$1 🎯

0 · Reply

swingtraderqueen Feb. 6 at 4:11 PM

$HOWL so underrated and undervalued. Price pt $5

0 · Reply

Spartrap Feb. 5 at 1:57 PM

1 · Reply

FrankyNyc Feb. 2 at 3:39 PM

$HOWL someone is buying up shares? how else did the stock bounce back green? If we close above 0.70 no doubt someone is accumulating

0 · Reply

FrankyNyc Feb. 2 at 3:09 PM

$HOWL over 200k in the first 30 minutes of trading. Definitely feels like Luke and his associates are still unloading

0 · Reply

FrankyNyc Feb. 2 at 2:52 PM

$HOWL Does anyone know if Luke Evnin is still unloading shares? so far theres no update of him unloading. I was hoping if he eventually stops the stock will bounce back to 1.00

0 · Reply

FrankyNyc Jan. 30 at 11:16 PM

1 · Reply

FrankyNyc Jan. 30 at 5:30 PM

$HOWL anemic volume today especially compared to january 28, when it had 1,045,800 and popped to 0.80 Last update was on December 18. We need an update.

0 · Reply

FrankyNyc Jan. 29 at 4:17 PM

$HOWL Hopefullly we stay above 0.70 and close green.

1 · Reply

FrankyNyc Jan. 29 at 2:57 PM

$HOWL Hmmm did Luke Evnin and his cronies kill the momentum?

0 · Reply

peepthestamp Jan. 29 at 1:09 PM

$HOWL

0 · Reply

zawojak Jan. 29 at 8:03 AM

$NUVB $ONDS $AQST $HOWL I wonder why is that 🥲 https://archive.is/2026.01.26-130140/https://www.bloomberg.com/news/articles/2026-01-26/blackrock-says-europe-draws-a-decade-in-a-year-of-stock-flows

0 · Reply

FrankyNyc Jan. 28 at 5:37 PM

$HOWL They pumped it to 0.80 only to dump it to 0.70

1 · Reply